Abstract: A method is provided for the treatment of sleep apnea and other conditions wherein an effective amount of crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride of formula (I): optionally comprising water up to 6%, and having an X-ray diffractogram that comprises characteristic peaks (2?) at 11.2°, 19.9°, 20.7° and 34.1°±0.2° is administered to a patient in need thereof.

Abstract: A method is provided for the treatment of sleep apnea and other conditions wherein an effective amount of crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride of formula (I): optionally comprising water up to 6%, and having an X-ray diffractogram that comprises characteristic peaks (2?) at 11.2°, 19.9°, 20.7° and 34.1°±0.2° is administered to a patient in need thereof.

Abstract: The invention relates to new crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride, the respective manufacture and methods of use, and compositions containing such a compound.

Abstract: The invention relates to new crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride, the respective manufacture and methods of use, and compositions containing such a compound.

Abstract: Use of a compound of formula (A), wherein: W is a residue which imparts antagonistic and/or agonistic activity at histamine H3-receptors when attached to an imidazole ring in 4(5) position; R1 and R2 may be identical or different and represent each independently a lower alkyl or cycloalkyl, or taken together with the nitrogen atom to which they are attached, a saturated nitrogen-containing ring (i) as defined, a non-aromatic unsaturated nitrogen-containing ring (ii) as defined, a morpholino group, or a N-substituted piperazino group as defined for preparing medicaments acting as antagonists and/or agonists at the H3-receptors of histamine.

Abstract: A compound selected from the group consisting of a compound of the formula ##STR1## having antagonist properties to histamine H.sub.3 -receptors.

Abstract: A compound selected from the group consisting of a compound of the formula ##STR1## wherein the substituents are defined as in the specification having antagonist properties to histamine H.sub.3 -receptors.

Abstract: Agonist compounds of the histamine H.sub.3 receptor for therapeutic use, pharmaceutical compositions acting as agonists of the said receptor and preparation process are disclosed.The compounds are derived from an amine R-NH.sub.2 having a high affinity for the histamine H.sub.3 receptor and to the primary amine function of which a group which gives rise to a bond that is capable of being slowly hydrolyzed in a neutral medium is attached. The pharmaceutical compositions contain these compounds and a pharmaceutically acceptable vehicle or excipient.These compounds are used for producing a medicinal product which inhibits the synthesis and the release of histamine, in particular, possessing sedative, sleep-regulating, anticonvulsant, antidepressant, anti-allergic, anti-inflammatory, antisecretory or anti-ulcerous effects.

Abstract: Arylalkylamine derivatives of the general formula ##STR1## are described which, owing to their anatagonistic action against histamine H.sub.1 - and H.sub.2 -receptors, can be used for the prophylaxis and treatment of disorders in which histamine is involved. They are prepared in a manner known per se.

Abstract: The present invention relates to .alpha.,.beta.-dimethylhistamine, of the rmula: ##STR1## in racemic form, or an optical isomer form or mixture of diastereoisomers and its acid addition salts. It may be prepared from an alkyl 2-amino 3-(1H-imidazol-4-yl)-carboxylate.

Abstract: New imidazolylalkyl-guanidine derivatives are described, which by virtue of their agonistic action on histamine-H.sub.2 receptors and in part also due to their additional H.sub.1 -antagonistic receptor activity can be used in the treatment of cardiac diseases, certain forms of hypertension and diseases of arterial occlusion.

Abstract: New guanidine carboxylic acid esters corresponding to the general formula I ##STR1## and a process for the preparation of these compounds are described. The compounds according to the invention are H.sub.2 -agonists optionally having an additional H.sub.1 -antagonistic component. They are distinguished by their improved oral activity. The use of the above-mentioned guanidine carboxylic acid esters and of pharmaceutical preparations containing these esters is also described.

Abstract: New imidazolyl guanidine derivatives corresponding to the following general formula ##STR1## are described. These compounds may be used in cardiac diseases, certain forms of hypertension and in diseases of arterial occlusion on account of their agonistic action on histamine-H.sub.2 receptors and in part their additional H.sub.1 -antagonistic receptor activity.

Abstract: The invention relates to a pharmaceutical composition containing histamine derivatives and to a method for treating diseases which involve histamine release and synthesis in the human or animal body.

Abstract: New compounds which act on the cardiac circulation and correspond to the general formula ##STR1## and may be used for the treatment of cardiac diseases, in certain forms of hypertension and in diseases of arterial occlusion are described.Methods of preparation for these compounds and medicaments containing these compounds are also described.

Abstract: 1,3,4-Thiadiazole derivatives corresponding to the general formula I ##STR1## which constitute highly effective inhibitors for histamine-H.sub.2 receptors are described. These compounds in addition have a cytoprotective action.

Abstract: 3,4-Diazole derivatives corresponding to the general formula I ##STR1## which exert a highly selective action on histamine-H.sub.2 receptors are described. Processes for the preparation of these compounds and pharmaceutical preparations containing these compounds are also described.

Abstract: A compound selected from the group consisting of a compound of the formula wherein the substituents are defined as in the specification having antagonist properties to histamine H3-receptors.